Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
67%(2 trials)

Phase Distribution

Ph not_applicable
2
67%

Phase Distribution

0

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution2 total trials
N/ANon-phased studies
2(100.0%)

Highest Phase Reached

Unknown

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Completed(3)

Detailed Status

Completed3

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
N/A

Trials by Phase

N/A2 (100.0%)

Trials by Status

completed3100%

Recent Activity

0 active trials
Showing 3 of 3
completed

Real-world Use of Hybrid Closed Loop in Adolescents and Young Adults 15-25 Years of Age with Type 1 Diabetes

NCT06253351
completednot_applicable

Safety and Efficacy of Initializing the Control-IQ Artificial Pancreas System Using Total Daily Insulin

NCT03804983
completednot_applicable

Diabetes Closed-Loop Project 6 (DCLP6): Fully Automated Closed-Loop Control in Type 1 Diabetes Using Meal Anticipation

NCT04877730

Clinical Trials (3)

Showing 3 of 3 trials
NCT06253351

Real-world Use of Hybrid Closed Loop in Adolescents and Young Adults 15-25 Years of Age with Type 1 Diabetes

Completed
NCT03804983Not Applicable

Safety and Efficacy of Initializing the Control-IQ Artificial Pancreas System Using Total Daily Insulin

Completed
NCT04877730Not Applicable

Diabetes Closed-Loop Project 6 (DCLP6): Fully Automated Closed-Loop Control in Type 1 Diabetes Using Meal Anticipation

Completed

All 3 trials loaded

Drug Details

Intervention Type
DEVICE
Total Trials
3